Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca2+ -mediated apoptosis pathways in MCF-7/ADR and K562/ADR.

@article{Sun2018TargetingPA,
  title={Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca2+ -mediated apoptosis pathways in MCF-7/ADR and K562/ADR.},
  author={Yaoting Sun and Changyuan Wang and Qiang Meng and Zhihao Liu and Xiaokui Huo and Pengyuan Sun and Huijun Sun and Xiaodong Ma and Jinyong Peng and Kexin Liu},
  journal={Journal of cellular physiology},
  year={2018},
  volume={233 4},
  pages={3066-3079}
}
Recently, a new target Ca2+ -binding protein SORCIN was reported to participate in multidrug resistance (MDR) in cancer. Here we aim to investigate whether dihydromyricetin (DMY), a dihydroflavonol compound with anti-inflamatory, anti-oxidant, anti-bacterial and anti-tumor actions, reverses MDR in MCF-7/ADR and K562/ADR and to elucidate its potential molecular mechanism. DMY enhanced cytotoxicity of adriamycin (ADR) by downregulating MDR1 mRNA and P-gp expression through MAPK/ERK pathway and… CONTINUE READING
2 Citations
0 References
Similar Papers